Dorsavi
- Short interest
- 0.01%
- −0.05 pp 30d
- as of 4 June 2026
- Reported shorts
- 124.8K
- Shares on issue
- 1.210B
Dorsavi (DVL) Short Interest
Dorsavi (ASX:DVL) had 0.01% of shares reported as short positions as of 4 June 2026, representing 124,850 shares. Dorsavi operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Dorsavi
Dorsavi (DVL) specializes in medical research and development, providing advanced wearable sensor technology for medical, sporting, and occupational health and safety applications. Their unique value lies in their revolutionary wireless technology, which accurately and objectively measures and analyzes human movement and muscle activity using patented algorithms, offering quality data without the need for a lab environment.
Company profile →Dorsavi (ASX:DVL) has 0.01% of its shares on issue reported as short positions as of 4 June 2026, or about 124,850 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. DVL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads DVL today
- Zanger BreakoutWatchScore 13rank 1566 of 1942
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 7rank 1510 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
DVL fundamentals
In the year to 30 Jun 2026, Dorsavi (ASX:DVL) recorded revenue of A$1.6M and a net loss after tax of A$8.5M. A year earlier it recorded revenue of A$1.5M and a net loss after tax of A$1.5M. Year-on-year growth: revenue +5.8% (FY). Net margin −535.4% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest DVL news
All news- Annual General Meeting
asx · 11 Oct 2026
- dorsaVi (ASX:DVL) Outlines Broker Placement to Support Three-Vertical Strategy - Kalkine
googlenews · 6 Oct 2026
- Proposed issue of securities - DVL
asx · 5 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss DVL
Start a research thread or post the first pulse update